Bank of New York Mellon Corp Acquires New Stake in MBX Biosciences, Inc. (NYSE:MBX)

Bank of New York Mellon Corp bought a new stake in shares of MBX Biosciences, Inc. (NYSE:MBX) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 23,914 shares of the company’s stock, valued at approximately $441,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. The Manufacturers Life Insurance Company acquired a new stake in shares of MBX Biosciences during the third quarter worth about $1,200,000. NEA Management Company LLC purchased a new stake in MBX Biosciences during the 3rd quarter worth approximately $93,904,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in MBX Biosciences during the 3rd quarter worth approximately $278,000. Maven Securities LTD acquired a new stake in MBX Biosciences during the 3rd quarter worth approximately $1,299,000. Finally, Point72 Asset Management L.P. purchased a new position in MBX Biosciences in the 3rd quarter valued at approximately $405,000.

Insider Buying and Selling

In related news, Director Carl L. Gordon acquired 143,170 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was acquired at an average price of $10.84 per share, for a total transaction of $1,551,962.80. Following the purchase, the director now owns 3,255,000 shares of the company’s stock, valued at $35,284,200. This represents a 4.60 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO P. Kent Hawryluk acquired 50,000 shares of the stock in a transaction dated Tuesday, February 4th. The shares were bought at an average cost of $10.69 per share, with a total value of $534,500.00. Following the completion of the transaction, the chief executive officer now owns 448,277 shares of the company’s stock, valued at approximately $4,792,081.13. This represents a 12.55 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased 240,672 shares of company stock valued at $2,555,308 in the last three months.

MBX Biosciences Price Performance

NYSE:MBX opened at $7.41 on Friday. MBX Biosciences, Inc. has a 52 week low of $7.38 and a 52 week high of $27.50. The stock has a fifty day simple moving average of $9.93.

MBX Biosciences Profile

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.